These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
650 related articles for article (PubMed ID: 22356288)
21. Present therapeutic role of cholesteryl ester transfer protein inhibitors. Ferri N; Corsini A; Sirtori CR; Ruscica M Pharmacol Res; 2018 Feb; 128():29-41. PubMed ID: 29287689 [TBL] [Abstract][Full Text] [Related]
22. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction. Schaefer EJ; Asztalos BF Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849 [TBL] [Abstract][Full Text] [Related]
23. The therapeutic potential of CETP inhibitors: a patent review. Wang X; Li W; Hao L; Xie H; Hao C; Liu C; Li W; Xiong X; Zhao D Expert Opin Ther Pat; 2018 Apr; 28(4):331-340. PubMed ID: 29424255 [TBL] [Abstract][Full Text] [Related]
24. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Chapman MJ; Le Goff W; Guerin M; Kontush A Eur Heart J; 2010 Jan; 31(2):149-64. PubMed ID: 19825813 [TBL] [Abstract][Full Text] [Related]
25. [HDL and CETP in atherogenesis]. Pöss J; Böhm M; Laufs U Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258 [TBL] [Abstract][Full Text] [Related]
26. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Sofat R; Hingorani AD; Smeeth L; Humphries SE; Talmud PJ; Cooper J; Shah T; Sandhu MS; Ricketts SL; Boekholdt SM; Wareham N; Khaw KT; Kumari M; Kivimaki M; Marmot M; Asselbergs FW; van der Harst P; Dullaart RP; Navis G; van Veldhuisen DJ; Van Gilst WH; Thompson JF; McCaskie P; Palmer LJ; Arca M; Quagliarini F; Gaudio C; Cambien F; Nicaud V; Poirer O; Gudnason V; Isaacs A; Witteman JC; van Duijn CM; Pencina M; Vasan RS; D'Agostino RB; Ordovas J; Li TY; Kakko S; Kauma H; Savolainen MJ; Kesäniemi YA; Sandhofer A; Paulweber B; Sorli JV; Goto A; Yokoyama S; Okumura K; Horne BD; Packard C; Freeman D; Ford I; Sattar N; McCormack V; Lawlor DA; Ebrahim S; Smith GD; Kastelein JJ; Deanfield J; Casas JP Circulation; 2010 Jan; 121(1):52-62. PubMed ID: 20026784 [TBL] [Abstract][Full Text] [Related]
27. Refocusing on use of cholesteryl ester transfer protein inhibitors. Kastelein JJ Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853 [TBL] [Abstract][Full Text] [Related]
28. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. Rhainds D; Arsenault BJ; Brodeur MR; Tardif JC Future Cardiol; 2012 Jul; 8(4):513-31. PubMed ID: 22871191 [TBL] [Abstract][Full Text] [Related]
29. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk? Schaefer EJ Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567 [TBL] [Abstract][Full Text] [Related]
30. The end of the road for CETP inhibitors after torcetrapib? Joy T; Hegele RA Curr Opin Cardiol; 2009 Jul; 24(4):364-71. PubMed ID: 19522058 [TBL] [Abstract][Full Text] [Related]
31. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents. Shinkai H Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630 [TBL] [Abstract][Full Text] [Related]
32. Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease. Furtado JD; Ruotolo G; Nicholls SJ; Dullea R; Carvajal-Gonzalez S; Sacks FM Arterioscler Thromb Vasc Biol; 2022 Feb; 42(2):227-237. PubMed ID: 34937388 [TBL] [Abstract][Full Text] [Related]
33. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. Barter PJ; Rye KA J Lipid Res; 2012 Sep; 53(9):1755-66. PubMed ID: 22550134 [TBL] [Abstract][Full Text] [Related]
35. Cholesteryl ester transfer protein inhibitors in precision medicine. Su X; Li G; Deng Y; Chang D Clin Chim Acta; 2020 Nov; 510():733-740. PubMed ID: 32941836 [TBL] [Abstract][Full Text] [Related]
36. Therapeutic targets to raise HDL in patients at risk or with coronary artery disease. Lüscher TF; von Eckardstein A; Simic B Curr Vasc Pharmacol; 2012 Nov; 10(6):720-4. PubMed ID: 23259565 [TBL] [Abstract][Full Text] [Related]
37. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice. Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533 [TBL] [Abstract][Full Text] [Related]